CSI Market
Sign In | Register

Oncternal Therapeutics Inc (ONCT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ONCT Annual Cash Flow →
Cash flow patterns shown here provide context for understanding Oncternal Therapeutics Inc's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-25.41
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation4.60
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Noncash Lease Expense0.10
Noncash Compensation Expense-
Increase Decrease In Operating Lease Liability-0.13
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.05
Increase (Decrease) in Accrued Liabilities-0.28
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.35
Other Working Capital0.13
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.63
Discontinued operations0.00
Net Cash flow from Operating Activities-20.21
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities43.00
Payments to Acquire Available-for-sale Securities, Debt-16.32
Real Estate Investments0.00
Proceeds From Divestiture Of Businesses Net Of Cash Expenses-
Payments For Proceeds From Heldtomaturity Securities Shortterm-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities26.68
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.09
Payments On Capital Lease And Financed Equipment Obligations-
Payments For Settlement Of Fractional Shares Reverse Stock Split-
Proceeds From Stock Options Exercised And Warrant Exercises-
Proceeds From Stock Options Exercised And Warrant Exercises-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.09
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-20.21
Total Cash Flow6.38
4 historic quarters locked

Sign in to unlock the full Oncternal Therapeutics Inc cash flow history.

Sign In Create Free Account

About Oncternal Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-122383

Figures are derived from filed reports and may be restated. Historical data is subject to revision.